Richard E Pratley MDSenior Investigator and Diabetes Program Lead, AdventHealth Orlando Translational Research Institute for Metabolism and Diabetes; Medical Director, AdventHealth Diabetes Institute, Orlando, Florida
Dr. Richard Pratley, an internationally recognized expert in diabetes, is Senior Investigator and Diabetes Program Lead at the AdventHealthOrlando Translational Research Institute for Metabolism and Diabetes and the Medical Director of the AdventHealth Diabetes Institute in Orlando.
Dr. Pratley is a principal investigator for both NIH- and pharmaceutical company–sponsored trials in diabetes and obesity, and his current research interests include the prevention of diabetes, improving the care of individuals with diabetes, developing new drugs to treat and prevent diabetes and its complications, and understanding the role of the fat cell in increasing the risk for diabetes and heart disease. He presents his research regularly at national and international meetings and has written over 240 peer-reviewed articles. He is a member of the American Diabetes Association, the European Association for the Study of Diabetes, and the Obesity Society. He serves on the editorial boards of The Lancet Diabetes and Endocrinology, The Journal of Clinical Endocrinology & Metabolism, and the Journal of Diabetes and Its Complications.
After receiving his medical degree from Wayne State University in Detroit and undergoing residency training in internal medicine the University of Michigan in Ann Arbor, he completed fellowships in geriatric medicine and gerontology at the University of Michigan, Johns Hopkins University, and the National Institute on Aging.
Senior Investigator and Diabetes Program Lead, AdventHealth Orlando Translational Research Institute for Metabolism and Diabetes; Medical Director, AdventHealth Diabetes Institute
MD: Wayne State University, Detroit, Michigan
Fellowship (geriatric medicine and gerontology): University of Michigan, Johns Hopkins University, National Institute on Aging
Prevention of diabetes; improving the care of individuals with diabetes; developing new drugs to treat and prevent diabetes and its complications; understanding the role of the fat cell in increasing the risk for diabetes and heart disease
Dr. Pratley reports speaker and consulting fees from AstraZeneca; consulting fees from Boehringer-Ingelheim; consulting fees from Eisai, Inc.; consulting fees from GlaxoSmithKline; consulting fees from Glytec, LLC; consulting fees from Janssen; grants from Lexicon Pharmaceuticals; grants and consulting fees from Ligand Pharmaceuticals, Inc;, grants and consulting fees from Lilly; grants and consulting fees from Merck; consulting fees from Mundipharma; grants, speaker fees and consulting fees from Novo Nordisk; consulting fees from Pfizer; grants and consulting fees from Sanofi; grants, speaker fees and consulting fees from Takeda; personal consulting fees from Sanofi US Services, Inc., outside the submitted work. Except for consulting fees in February 2018 and June 2018 from Sanofi US Services, Inc., Dr. Richard Pratley's services were paid for directly to AdventHealth, a nonprofit organization.
Recent Contributions to PracticeUpdate:
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age
- 2019 Top Stories in Diabetes: Oral Semaglutide for the Treatment of Type 2 Diabetes
- Use and Discontinuation of Insulin Treatment Among Older Adults With Type 2 Diabetes
- Oral Semaglutide vs Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin
- Oral Semaglutide Is Safe and Effective Added to Insulin ± Metformin in Patients With T2D
- The Association Between Polypharmacy and Adverse Health Consequences in Elderly Patients With Type 2 Diabetes
- Efficacy and Safety of Oral Semaglutide With Flexible Dose Adjustment vs Sitagliptin in Type 2 Diabetes
- DPP-4 Inhibitors and Risk of IBD Among Patients With Type 2 Diabetes
- ADA Scientific Sessions 2019: Recommendations From Dr. Richard Pratley
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea